Compare Mandiri Herindo Adiperkasa Tbk. (MAHA) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mandiri Herindo Adiperkasa Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Mandiri Herindo Adiperkasa Tbk. trades at Rp145 (market cap 2.42T, 4.28M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Mandiri Herindo Adiperkasa Tbk. is far larger — about 23.2× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| MAHA | SCPI | |
|---|---|---|
Market Cap | 2.42T | 104.4B |
Volume | 4.28M | — |
Lot | 42.79K | — |
Turnover | 613.55M | — |
Average Price | 143.4 | — |
Value | 613.55M | — |
Indicative Equilibrium Price | 145 | — |
Indicative Equilibrium Volume | 48 | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mandiri Herindo Adiperkasa Tbk.
PT Mandiri Herindo Adiperkasa Tbk. (the Company) is a limited liability company established in the Republic of Indonesia based on Notarial Deed of Julia Rochana Murat, S.H., No. 18 dated January 25, 1994. The Company started commercial activities in 1994.
Read more on MAHA →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
